CSL share price lifts as plasma collections continue recovery

What's boosting the CSL share price today?

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price is up nearly 2% today 
  • In today's news, CSL advised plasma collections are now at pre-COVID-19 levels 
  • The company's share price has descended 5% year to date 

The CSL Ltd (ASX: CSL) share price is in the green today after the company presented at the 2022 Macquarie Australia Conference in Sydney.

CSL shares are currently swapping hands at $275.38, a 1.82% gain. In contrast, the S&P/ASX 200 Index (ASX: XJO) is 0.1% lower at the time of writing.

Let's take a look at what CSL reported today.

Why is the CSL share price lifting?

CSL informed the market that plasma collections are now at roughly the same level as prior to the COVID-19 pandemic.

In a presentation at the Macquarie conference, CSL also advised the company's gross margin is predicted to return to pre-COVID levels in the future. CSL is working on technology improvements to plasma collection, reducing donation time by 30%.

CSL reported capital expenditure (CAPEX) is expected to be about $1.2 billion in FY22.

The company also highlighted the benefits of the Vifor Pharma acquisition. CSL is expecting regulatory approvals and closure on this deal by mid-2022.

CSL conducted a $750 million share plan for the acquisition in February, receiving strong support.

The CSL share price climbed nearly 2% in April amid multiple positive broker notes. Citi has placed a $335 price target on the company's share price. This is nearly a 22% upside on the current share price.

CSL is predicting a net profit after tax (NPAT) of between $2.15 to $2.25 billion in FY22.

CSL share price snapshot

The CSL share price has climbed 1.55% in the past year but it has fallen more than 5% year to date.

For perspective, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned nearly 5% over the past year.

CSL has a market capitalisation of about $132.6 billion based on today's share price.

Should you invest $1,000 in CSL right now?

Before you buy CSL shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and CSL wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man and a woman sit in front of a laptop looking fascinated and captivated.
Healthcare Shares

Guess which ASX 200 company co-founders just sold $118 million in shares

This ASX 200 healthcare share is trading lower following the mammoth off-market block trade.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Mesoblast share price rips 12% on financial and operational updates

Mesoblast has set a price for its recently-approved flagship drug, which will go to market over the next few weeks.

Read more »

Six smiling health workers pose for a selfie.
Earnings Results

Medibank share price jumps 7% on strong half-year profit growth

Let's see how the health insurance giant performed during the half.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Earnings Results

This ASX healthcare stock is crashing 30% on half year results

Why is this stock crashing deep into the red today? Let's find out.

Read more »

Buy, hold and sell ratings written on signs on a wooden pole.
Healthcare Shares

CSL shares: Buy, sell or hold in 2025?

Three investment experts offer their view on the outlook for CSL shares.

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Earnings Results

Why has this ASX 200 healthcare stock crashed 24% in 2 days?

It has been a tough start to the week for this medical device company's shareholders.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

This little-known healthcare company is now the 17th-largest business in the ASX 200

This stock isn’t well-known, but it’s a market leader with significant potential.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why I think this ASX small-cap share is a buy at $1.18

After falling almost 17% over the past year, I see a lot of value at the current price.

Read more »